{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:02:04Z","timestamp":1786982524099,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China,China","doi-asserted-by":"crossref","award":["82173045"],"award-info":[{"award-number":["82173045"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China,China","doi-asserted-by":"crossref","award":["81602215"],"award-info":[{"award-number":["81602215"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bladder cancer (BC) remains a prevalent malignancy worldwide, with rising incidence rates each year. Despite progress in therapeutic strategies, many patients suffer recurrence or progression, emphasizing the urgent need for novel prognostic biomarkers and therapeutic targets. This research evaluated the prognostic relevance and functional role of Cleavage and Polyadenylation Specificity Factor 3 (CPSF3) in BC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed CPSF3 expression using The Cancer Genome Atlas data and immunohistochemistry on a cohort of 203 BC patients. A nomogram incorporating CPSF3 expression was developed based on CPSF3 expression for prediction of overall survival and disease-free survival. Immune infiltration analyses and transcriptome sequencing were performed to explore underlying biological mechanisms. In vitro and in vivo experiments were utilized to examine the results of CPSF3 silencing on bladder cancer cell growth, colony-forming ability and cell cycle transitions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Elevated CPSF3 expression was significantly linked to unfavorable overall survival and disease-free survival both in TCGA datasets and our cohort. The CPSF3-based nomogram outperformed conventional prognostic models. CPSF3 expression was associated with tumor-infiltrating immune cells and immune checkpoint markers. Enrichment analysis revealed CPSF3 enrichment in cell cycle-related pathways. Suppression of CPSF3 expression led to marked reductions in cell proliferation, colony formation, tumor growth in animal models and inhibited G1 to S phase progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CPSF3 is a promising prognostic biomarker for BC and may play a crucial role in BC progression. Incorporating CPSF3 into clinical prognostic models may enhance prediction of patient outcomes. CPSF3 may represent a promising therapeutic target for BC management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12672-025-03672-z","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T08:02:33Z","timestamp":1760083353000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comprehensive investigation identifies CPSF3 as a novel prognostic and oncogenic biomarker in bladder cancer"],"prefix":"10.1007","volume":"16","author":[{"given":"Zhiyang","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yining","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danfeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenghe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"issue":"1","key":"3672_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"3672_CR2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk M, Burger M, Capoun O, et al. European association of urology guidelines on Non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in Situ). Eur Urol. 2022;81(1):75\u201394.","journal-title":"Eur Urol"},{"issue":"1","key":"3672_CR3","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1097\/JS9.0000000000000790","volume":"110","author":"S Lai","year":"2024","unstructured":"Lai S, Liu J, Lai CH, et al. Prognostic variations between \u2018primary\u2019 and \u2018progressive\u2019 muscle-invasive bladder cancer following radical cystectomy: a novel propensity score-based multicenter cohort study. Int J Surg. 2024;110(1):270\u20139.","journal-title":"Int J Surg"},{"key":"3672_CR4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ctrv.2019.04.002","volume":"76","author":"R Nadal","year":"2019","unstructured":"Nadal R, Bellmunt J. Management of metastatic bladder cancer. Cancer Treat Rev. 2019;76:10\u201321.","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"3672_CR5","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41585-019-0208-0","volume":"16","author":"C Alifrangis","year":"2019","unstructured":"Alifrangis C, McGovern U, Freeman A, Powles T, Linch M. Molecular and histopathology directed therapy for advanced bladder cancer. Nat Rev Urol. 2019;16(8):465\u201383.","journal-title":"Nat Rev Urol"},{"issue":"7121","key":"3672_CR6","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1038\/nature05363","volume":"444","author":"CR Mandel","year":"2006","unstructured":"Mandel CR, Kaneko S, Zhang H, et al. Polyadenylation factor CPSF-73 is the pre-mRNA 3\u2019-end-processing endonuclease. Nature. 2006;444(7121):953\u20136.","journal-title":"Nature"},{"issue":"16","key":"3672_CR7","doi-asserted-by":"publisher","first-page":"4057","DOI":"10.3390\/cancers15164057","volume":"15","author":"Y Huang","year":"2023","unstructured":"Huang Y, Ji H, Dong J, et al. CPSF3 promotes Pre-mRNA splicing and prevents circrna cyclization in hepatocellular carcinoma. Cancers (Basel). 2023;15(16):4057.","journal-title":"Cancers (Basel)"},{"key":"3672_CR8","doi-asserted-by":"publisher","first-page":"e33111","DOI":"10.7554\/eLife.33111","volume":"6","author":"M Clerici","year":"2017","unstructured":"Clerici M, Faini M, Aebersold R, Jinek M. Structural insights into the assembly and polya signal recognition mechanism of the human CPSF complex. Elife. 2017;6:e33111.","journal-title":"Elife"},{"key":"3672_CR9","doi-asserted-by":"crossref","unstructured":"Chan S, Choi EA, Shi Y. Pre-mRNA 3\u2019-end processing complex assembly and function. Wiley Interdiscip Rev RNA. 2011; May-Jun;2(3):321\u201335.","DOI":"10.1002\/wrna.54"},{"issue":"19","key":"3672_CR10","doi-asserted-by":"publisher","first-page":"5799","DOI":"10.1093\/nar\/18.19.5799","volume":"18","author":"MD Sheets","year":"1990","unstructured":"Sheets MD, Ogg SC, Wickens MP. Point mutations in AAUAAA and the Poly (A) addition site: effects on the accuracy and efficiency of cleavage and Polyadenylation in vitro. Nucleic Acids Res. 1990;18(19):5799\u2013805.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"3672_CR11","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41589-019-0424-1","volume":"16","author":"NT Ross","year":"2020","unstructured":"Ross NT, Lohmann F, Carbonneau S, et al. CPSF3-dependent pre-mRNA processing as a druggable node in AML and ewing\u2019s sarcoma. Nat Chem Biol. 2020;16(1):50\u20139.","journal-title":"Nat Chem Biol"},{"issue":"21","key":"3672_CR12","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1101\/gad.250985.114","volume":"28","author":"L Sch\u00f6nemann","year":"2014","unstructured":"Sch\u00f6nemann L, K\u00fchn U, Martin G, et al. Reconstitution of CPSF active in polyadenylation: recognition of the polyadenylation signal by WDR33. Genes Dev. 2014;28(21):2381\u201393.","journal-title":"Genes Dev"},{"issue":"1","key":"3672_CR13","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41421-024-00654-3","volume":"10","author":"P Lin","year":"2024","unstructured":"Lin P, Chen W, Long Z, et al. RBBP6 maintains glioblastoma stem cells through CPSF3-dependent alternative polyadenylation. Cell Discov. 2024;10(1):32.","journal-title":"Cell Discov"},{"key":"3672_CR14","doi-asserted-by":"publisher","first-page":"106448","DOI":"10.1016\/j.compbiomed.2022.106448","volume":"153","author":"N Wang","year":"2023","unstructured":"Wang N, Li Y, Zhou X, Wang X, Yang G. Comprehensive analysis identifies ARHGEF6 as a potential prognostic and immunological biomarker in lung adenocarcinoma. Comput Biol Med. 2023;153:106448.","journal-title":"Comput Biol Med"},{"issue":"11","key":"3672_CR15","doi-asserted-by":"publisher","first-page":"3580","DOI":"10.7150\/jca.94360","volume":"15","author":"R Wan","year":"2024","unstructured":"Wan R, Pan L, Wang Q, et al. Decoding gastric cancer: machine learning insights into the significance of COMMDs family in immunotherapy and diagnosis. J Cancer. 2024;15(11):3580\u201395.","journal-title":"J Cancer"},{"key":"3672_CR16","doi-asserted-by":"crossref","unstructured":"Zhang H, Zhang G, Xu P, et al. Optimized dynamic network biomarker Deciphers a High-Resolution heterogeneity within thyroid cancer molecular subtypes. Med Res. 2025 April;29:1:10\u201331.","DOI":"10.1002\/mdr2.70004"},{"issue":"19","key":"3672_CR17","doi-asserted-by":"publisher","first-page":"10146","DOI":"10.18632\/aging.205063","volume":"15","author":"K Liang","year":"2023","unstructured":"Liang K, Guo Z, Zhang S, et al. GPR37 expression as a prognostic marker in gliomas: a bioinformatics-based analysis. Aging. 2023;15(19):10146\u201367.","journal-title":"Aging"},{"key":"3672_CR18","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ejca.2022.05.040","volume":"172","author":"V Derang\u00e8re","year":"2022","unstructured":"Derang\u00e8re V, Lecuelle J, Lepage C, et al. Combination of CDX2 H-score quantitative analysis with CD3 AI-guided analysis identifies patients with a good prognosis only in stage III colon cancer. Eur J Cancer. 2022;172:221\u201330.","journal-title":"Eur J Cancer"},{"issue":"4","key":"3672_CR19","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.immuni.2013.10.003","volume":"39","author":"G Bindea","year":"2013","unstructured":"Bindea G, Mlecnik B, Tosolini M, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39(4):782\u201395.","journal-title":"Immunity"},{"key":"3672_CR20","doi-asserted-by":"crossref","unstructured":"Fang Y, Kong Y, Rong G et al. Systematic investigation of tumor microenvironment and antitumor immunity with IOBR. Med Res 2025; March 26;1:136\u201340.","DOI":"10.1002\/mdr2.70001"},{"key":"3672_CR21","doi-asserted-by":"publisher","first-page":"1236435","DOI":"10.3389\/fonc.2023.1236435","volume":"13","author":"B Ye","year":"2023","unstructured":"Ye B, Wang Q, Zhu X, et al. Single-cell RNA sequencing identifies a novel proliferation cell type affecting clinical outcome of pancreatic ductal adenocarcinoma. Front Oncol. 2023;13:1236435.","journal-title":"Front Oncol"},{"issue":"1","key":"3672_CR22","doi-asserted-by":"publisher","first-page":"e3580","DOI":"10.1002\/jgm.3580","volume":"26","author":"Z Li","year":"2024","unstructured":"Li Z, Wang Q, Huang X, et al. Multi-omics analysis reveals that ferroptosis-related gene CISD2 is a prognostic biomarker of head and neck squamous cell carcinoma. J Gene Med. 2024;26(1):e3580.","journal-title":"J Gene Med"},{"issue":"5","key":"3672_CR23","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41419-020-2554-5","volume":"11","author":"Q Xiong","year":"2020","unstructured":"Xiong Q, Liu A, Ren Q, et al. Cuprous oxide nanoparticles trigger reactive oxygen species-induced apoptosis through activation of erk-dependent autophagy in bladder cancer. Cell Death Dis. 2020;11(5):366.","journal-title":"Cell Death Dis"},{"issue":"1","key":"3672_CR24","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s12920-023-01688-4","volume":"16","author":"S Zhao","year":"2023","unstructured":"Zhao S, Wang Q, Liu Y, et al. Interaction, immune infiltration characteristics and prognostic modeling of efferocytosis-related subtypes in glioblastoma. BMC Med Genomics. 2023;16(1):248.","journal-title":"BMC Med Genomics"},{"issue":"1","key":"3672_CR25","doi-asserted-by":"publisher","first-page":"275","DOI":"10.7150\/jca.89338","volume":"15","author":"Q Wang","year":"2024","unstructured":"Wang Q, Zheng C, Hou H, et al. Interplay of sphingolipid metabolism in predicting prognosis of GBM patients: towards precision immunotherapy. J Cancer. 2024;15(1):275\u201392.","journal-title":"J Cancer"},{"issue":"1","key":"3672_CR26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/onc.2008.359","volume":"28","author":"ZH Zhu","year":"2009","unstructured":"Zhu ZH, Yu YP, Shi YK, Nelson JB, Luo JH. CSR1 induces cell death through inactivation of CPSF3. Oncogene. 2009;28(1):41\u201351.","journal-title":"Oncogene"},{"issue":"9","key":"3672_CR27","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1101\/gad.261974.115","volume":"29","author":"Y Shi","year":"2015","unstructured":"Shi Y, Manley JL. The end of the message: multiple protein-RNA interactions define the mRNA polyadenylation site. Genes Dev. 2015;29(9):889\u201397.","journal-title":"Genes Dev"},{"issue":"6","key":"3672_CR28","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.3390\/ijms25063473","volume":"25","author":"A Vikerfors","year":"2024","unstructured":"Vikerfors A, Davidsson S, Carlsson J, Jerlstr\u00f6m T. Plasma levels of pentraxin 3: A potential prognostic biomarker in urinary bladder cancer patients. Int J Mol Sci. 2024;25(6):3473.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"3672_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/jcmm.18213","volume":"28","author":"Y Wang","year":"2024","unstructured":"Wang Y, Wang J, Zhang L, et al. Unveiling the role of YARS1 in bladder cancer: A prognostic biomarker and therapeutic target. J Cell Mol Med. 2024;28(7):1\u201320.","journal-title":"J Cell Mol Med"},{"key":"3672_CR30","doi-asserted-by":"publisher","first-page":"106976","DOI":"10.1016\/j.compbiomed.2023.106976","volume":"162","author":"PH Xu","year":"2023","unstructured":"Xu PH, Chen S, Wang Y, et al. FGFR3 mutation characterization identifies prognostic and immune-related gene signatures in bladder cancer. Comput Biol Med. 2023;162:106976.","journal-title":"Comput Biol Med"},{"issue":"3","key":"3672_CR31","first-page":"2835","volume":"18","author":"Y Ning","year":"2019","unstructured":"Ning Y, Liu W, Guan X, Xie X, Zhang Y. CPSF3 is a promising prognostic biomarker and predicts recurrence of non-small cell lung cancer. Oncol Lett. 2019;18(3):2835\u201344.","journal-title":"Oncol Lett"},{"issue":"5","key":"3672_CR32","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2217\/bmm-2021-0039","volume":"15","author":"N Li","year":"2021","unstructured":"Li N, Jiang S, Fu R, et al. Cleavage and polyadenylation-specific factor 3 induces cell cycle arrest via PI3K\/Akt\/GSK-3\u03b2 signaling pathways and predicts a negative prognosis in hepatocellular carcinoma. Biomark Med. 2021;15(5):347\u201358.","journal-title":"Biomark Med"},{"issue":"3","key":"3672_CR33","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1261\/rna.079931.123","volume":"30","author":"AA Alahmari","year":"2024","unstructured":"Alahmari AA, Chaubey AH, Jonnakuti VS, et al. CPSF3 Inhibition blocks pancreatic cancer cell proliferation through disruption of core histone mRNA processing. RNA. 2024;30(3):281\u201397.","journal-title":"RNA"},{"issue":"1","key":"3672_CR34","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1186\/s12885-022-10103-7","volume":"22","author":"M Xiong","year":"2022","unstructured":"Xiong M, Li W, Wang L, et al. Comprehensive analysis of alternative polyadenylation regulators concerning CD276 and immune infiltration in bladder cancer. BMC Cancer. 2022;22(1):1026.","journal-title":"BMC Cancer"},{"issue":"47","key":"3672_CR35","doi-asserted-by":"publisher","first-page":"eadj0123","DOI":"10.1126\/sciadv.adj0123","volume":"9","author":"P Shen","year":"2023","unstructured":"Shen P, Ye K, Xiang H, et al. Therapeutic targeting of CPSF3-dependent transcriptional termination in ovarian cancer. Sci Adv. 2023;9(47):eadj0123.","journal-title":"Sci Adv"},{"issue":"1","key":"3672_CR36","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/s13046-019-1263-3","volume":"38","author":"K Luo","year":"2019","unstructured":"Luo K, Geng J, Zhang Q, et al. LncRNA CASC9 interacts with CPSF3 to regulate TGF-\u03b2 signaling in colorectal cancer. J Exp Clin Cancer Res. 2019;38(1):249.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"3672_CR37","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.bbrc.2019.08.004","volume":"518","author":"J Kakegawa","year":"2019","unstructured":"Kakegawa J, Sakane N, Suzuki K, Yoshida T. JTE-607, a multiple cytokine production inhibitor, targets CPSF3 and inhibits pre-mRNA processing. Biochem Biophys Res Commun. 2019;518(1):32\u20137.","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03672-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-03672-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03672-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:36:35Z","timestamp":1760362595000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-03672-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3672"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-03672-z","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]},"assertion":[{"value":"8 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that all methods were performed in accordance with the Declaration of Helsinki. The research involving human subjects or animals was reviewed and approved by the Ethics Committee of Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University (No.KY2022-183, 3rd August 2022). Formal informed consents was obtained from all participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors affirm that human research participants provided formal informed consent for publication of the images in Figure\n                      \n                      and information in Table\n                      \n                      -\n                      \n                      .","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1847"}}